| Model Name | Description |
| KP4 | Derived from pancreatic ductal adenocarcinoma (PDAC); KRAS and TP53 mutant, SMAD4 wild-type; used to study growth factor signaling and cytotoxic drug response. |
| Panc 02.13 | PDAC model with mutant KRAS and TP53; exhibits epithelial morphology; used in targeted therapy and immunotherapy studies. |
| HPAC | Well-differentiated pancreatic adenocarcinoma; KRAS and TP53 mutant, expresses epithelial markers and mucins; used to evaluate chemoresistance. |
| HPAFII | Pancreatic adenocarcinoma with KRAS and TP53 mutations; E-cadherin–positive and moderately differentiated; useful in epithelial cell adhesion and drug penetration studies. |
| CFPAC-1 | KRAS G12V and TP53 mutant PDAC derived from a cystic fibrosis patient; CFTR-deficient; used in transporter and drug accumulation studies. |
| Panc 04.03 | PDAC model with mutant KRAS, TP53 wild-type; well-differentiated phenotype, used in early-stage drug development and genetic dependency screens. |
| CAPAN-2 | Pancreatic adenocarcinoma with KRAS G12V mutation and wild-type BRCA2; exhibits epithelial morphology; used in PI3K pathway and EGFR-targeted therapy testing. |
| Hs766T | Undifferentiated PDAC model with KRAS and TP53 mutations; desmoplastic stroma and hypoxic response make it ideal for microenvironment-focused therapies. |
| SW1990 | Well-differentiated pancreatic adenocarcinoma from metastatic lesion; KRAS and TP53 mutant; used to study metastasis and chemoresistance mechanisms. |